Health Care [ 4/12 ] | Biotechnology [ 13/75 ]
NASDAQ | Common Stock
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.
The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.
Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 16, 26 | -0.28 Increased by +28.21% | -0.32 Increased by +13.29% |
| Nov 13, 25 | -0.30 Increased by +21.05% | -0.35 Increased by +14.29% |
| Aug 12, 25 | -0.58 Decreased by -38.10% | -0.39 Decreased by -48.72% |
| May 8, 25 | -0.43 Increased by +6.52% | -0.45 Increased by +4.44% |
| Mar 10, 25 | -0.39 Increased by 0.00% | -0.42 Increased by +7.14% |
| Nov 7, 24 | -0.38 Decreased by -216.67% | -0.45 Increased by +15.56% |
| Aug 6, 24 | -0.42 Increased by +12.50% | -0.46 Increased by +8.70% |
| May 7, 24 | -0.46 Increased by 0.00% | -0.40 Decreased by -15.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 3.94 M Increased by +89.74% | -26.49 M Increased by +25.36% | Decreased by -672.11% Increased by +60.67% |
| Sep 30, 25 | 2.20 M Increased by +8.60% | -27.55 M Increased by +20.57% | Decreased by -1.25 K% Increased by +26.86% |
| Jun 30, 25 | 2.67 M Decreased by -23.01% | -54.10 M Decreased by -43.51% | Decreased by -2.03 K% Decreased by -86.39% |
| Mar 31, 25 | 2.35 M Decreased by -3.13% | -39.99 M Increased by +3.01% | Decreased by -1.70 K% Decreased by -0.12% |
| Dec 31, 24 | 2.08 M Decreased by -41.62% | -35.49 M Decreased by -2.85% | Decreased by -1.71 K% Decreased by -76.19% |
| Sep 30, 24 | 2.02 M Decreased by -91.45% | -34.68 M Decreased by -246.77% | Decreased by -1.71 K% Decreased by -3.95 K% |
| Jun 30, 24 | 3.46 M Decreased by -7.75% | -37.70 M Decreased by -27.70% | Decreased by -1.09 K% Decreased by -38.43% |
| Mar 31, 24 | 2.43 M Decreased by -30.64% | -41.23 M Decreased by -47.03% | Decreased by -1.70 K% Decreased by -111.98% |